Pipeline · Bill → Law
Step 1
Introduced
May 17, 2023
Step 2
Referred
May 19, 2023
E&C · HELP
Step 3
Committee
Sep 18, 2024
Reported out
Step 4
House floor
Step 5
Senate
Sep 24, 2024
Step 6
Resolve Changes
Step 7
Signed
SummaryCRS Summary
This bill authorizes certain targeted clinical trials involving combinations of drugs to treat pediatric cancer. Specifically, the bill modifies requirements relating to molecularly targeted pediatric cancer investigations so as to authorize investigations of new drugs that are used in combination with active ingredients that have already been approved and that (1) have been determined to be the standard of care for treating a pediatric cancer, or (2) have been approved to treat an adult cancer and are directed at molecular targets for pediatric cancer. The Food and Drug Administration must issue guidance and report on the bill's implementation. The Government Accountability Office must re...
6 provisions
1 provision
1 provision
Timeline · 15 actions
Sep 24, 2024
Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Sep 23, 2024
Mr. Bucshon moved to suspend the rules and pass the bill, as amended.
Sep 23, 2024
Considered under suspension of the rules.
Sep 23, 2024
DEBATE - The House proceeded with forty minutes of debate on H.R. 3433.
Sep 23, 2024
On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.
Sep 23, 2024
Motion to reconsider laid on the table Agreed to without objection.
Sep 20, 2024
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 118-700.
Sep 20, 2024
Placed on the Union Calendar, Calendar No. 594.
Sep 18, 2024
Committee Consideration and Mark-up Session Held
Sep 18, 2024
Ordered to be Reported (Amended) by the Yeas and Nays: 43 - 0.
May 16, 2024
Subcommittee Consideration and Mark-up Session Held
May 16, 2024
Forwarded by Subcommittee to Full Committee (Amended) by the Yeas and Nays: 16 - 11.
May 19, 2023
Referred to the Subcommittee on Health.
May 17, 2023
Introduced in House
May 17, 2023
Referred to the House Committee on Energy and Commerce.